New JDD Consensus Offers Practical Guidance on Cosibelimab for Advanced cSCC
Have you read this article from the JDD A recent expert consensus addresses cosibelimab, a newly FDA approved PD-L1 inhibitor for locally advanced and metastatic cutaneous squamous cell carcinoma and provides practical guidance for clinicians navigating treatment choices when surgery or radiation are not options.
The authors conducted a comprehensive literature review and convened a panel of nine dermatologists experienced in cSCC care. From more than 200 initial records, 13 relevant studies informed the discussion and a modified Delphi process produced six consensus statements. Five statements received unanimous endorsement with a top strength of recommendation. The review highlights cosibelimab’s clinical activity in laCSCC and mCSCC and reports a favorable safety profile, with no grade 4 or 5 immune related adverse events documented after over two years of follow up.
For practicing dermatologists and dermatology healthcare professionals, this paper distills available evidence on cosibelimab alongside expert interpretation, helping to frame where a PD-L1 inhibitor fits into the treatment landscape alongside PD-1 agents such as pembrolizumab and cemiplimab. The consensus prioritizes actionable considerations around efficacy and safety without overreaching beyond the published data.
If you manage patients with advanced cSCC and want to see the specific consensus statements, the strength of the recommendations, and how experts suggest integrating cosibelimab into practice, consult the full JDD article for the complete analysis and recommendations.
Blog write-up assisted by AI
